RNA-II: Key Enzyme in Transcription and Potential Drug Target

Target Name: Mediator of RNA Polymerase II Transcription

NCBI ID: P15737

Mediator of RNA Polymerase II Transcription

Other Name(s): None

RNA-II: Key Enzyme in Transcription and Potential Drug Target

RNA polymerase II (RNA-II) is a key enzyme in the process of transcription, which is the process by which the information contained in DNA is copied into RNA. This process is crucial for the development and maintenance of all living organisms. One of the critical roles of RNA-II is as a mediator in the regulation of gene expression, and it is involved in the transcription of a wide range of genes. Therefore, RNA-II has been identified as a potential drug target and a biomarker for various diseases.

RNA-II is a protein that consists of two subunits, alpha and beta subunits. The alpha subunit is responsible for the initiation of the transcription process, while the beta subunit is responsible for the elongation of the RNA chain. The alpha subunit has a critical role in the regulation of gene expression, as it is able to recognize specific sequences in the DNA that determine the start of the RNA sequence. The beta subunit, on the other hand, is responsible for the elongation of the RNA chain, and it is able to add the necessary base pairs to complete the RNA sequence.

One of the key features of RNA-II is its ability to recognize and transcribe specific sequences in the DNA. This is achieved through the use of a specific consensus sequence, known as the start site. The start site is a specific sequence of nucleotides that is located at the beginning of the DNA sequence that is being transcribed. RNA-II is able to recognize the start site and then initiate the transcription process.

RNA-II has been shown to play a role in the regulation of gene expression in various organisms, including humans. For example, studies have shown that RNA-II is involved in the regulation of gene expression in cancer cells. In these cells, RNA-II is often overexpressed, which allows the cells to resist the effects of cancer treatments. Additionally, RNA-II has also been shown to play a role in the regulation of gene expression in diseases such as cardiovascular disease and neurodegenerative diseases.

Another feature of RNA-II is its ability to form a complex with specific transcription factors. These transcription factors are proteins that are able to bind to specific DNA sequences and regulate the expression of genes. RNA-II has been shown to form a complex with several transcription factors, including the factors that regulate gene expression in cancer cells. This complexation allows RNA-II to regulate the expression of the genes it is transcribing, and it is a potential drug target for these diseases.

In addition to its role in gene expression, RNA-II has also been shown to play a role in the regulation of DNA replication. DNA replication is the process by which a cell makes an exact copy of its DNA before it divides. RNA-II is involved in the regulation of DNA replication in various organisms, including humans. For example, studies have shown that RNA-II is involved in the regulation of DNA replication in cancer cells. In these cells, RNA-II is often overexpressed, which allows the cells to continue to divide and proliferate.

Overall, RNA-II is a protein that plays a critical role in the process of transcription. Its ability to recognize and transcribe specific sequences in the DNA and to form a complex with transcription factors makes it a potential drug target and a biomarker for various diseases. Further research is needed to fully understand the role of RNA-II in gene expression and its potential as a drug target.

Protein Name: Mediator Of RNA Polymerase II Transcription

The "Mediator of RNA Polymerase II Transcription Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about Mediator of RNA Polymerase II Transcription comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets